Allogeneic Islet Cells Transplanted Onto the Omentum
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02213003|
Recruitment Status : Active, not recruiting
First Posted : August 11, 2014
Last Update Posted : February 28, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes Mellitus Hypoglycemia Hypoglycemia Unawareness||Biological: Islet transplantation||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Allogeneic Islet Cells Transplanted Onto the Omentum|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||May 2025|
|Estimated Study Completion Date :||May 2026|
Experimental: Islet transplantation
Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
Biological: Islet transplantation
Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
- A1c </= 6.5% and no severe hypoglycemia [ Time Frame: 1 year ]composite outcome
- procedural complications [ Time Frame: 1 year ]safety
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male and female patients age 18 to 65 years of age.
- Ability to provide written informed consent.
- Mentally stable and able to comply with the procedures of the study protocol.
- Type1 diabetes with onset of disease at <40 years of age, insulin-dependence for > 5 years at the time of enrollment
- Absent stimulated c-peptide (<0.3ng/mL) in response to a mixed meal tolerance test.
- Involvement in intensive diabetes management
- At least one episode of severe hypoglycemia in the 12 months prior to study enrollment.
- Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more OR A Hypoglycemia score greater than or equal to the 90th percentile (1047) during the screening period; OR Marked glycemic lability and defined by a lability index score greater than or equal to the 90th percentile (433 mmol/L2/h•wk-1) during the screening period; OR A composite of a Clarke score of 3 or less and a hypoglycemia score greater than or equal to the 75th percentile (423) and a lability index greater than or equal to the 75th percentile (329) during the screening period.
- Subjects screening data from 20053135 protocol will be accepted for subjects eligible for this study. If 20053135 visit was 12 months prior to enrollment, Visit 2 laboratory should be repeated.
- Body Mass Index (BMI) >30 kg/m2 or patient weight ≤50 kg.
- Insulin requirement of >1.0 IU/kg/day or <15 U/day.
- HbA1c >10%.
- Untreated proliferative diabetic retinopathy.
- Blood Pressure: SBP >160 mmHg or DBP >100 mmHg.
- Glomerular filtration rate <80 mL/min/1.73 m2 (calculated).
- Presence or history of macroalbuminuria (>300mg/g creatinine).
- Presence or history of panel-reactive anti-HLA antibodies.
- For female subjects: Serum or urine Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. If sexually active, subject must use at least two medically accepted methods of birth control.
- Presence or history of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB).
- Negative screen for Epstein-Barr Virus (EBV) by IgG determination.
- Invasive aspergillus, histoplasmosis, and coccidioidomycosis infection within one year prior to study enrollment.
- Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin.
- Active alcohol or substance abuse.
- Hb below the lower limits of normal at the local laboratory; lymphopenia (<1,000/µL), neutropenia (<1,500/µL), or thrombocytopenia (platelets <100,000/µL).
- A history of Factor V deficiency.
- Any coagulopathy or medical condition requiring long-term anticoagulant therapy.
Severe co-existing cardiac disease,
- recent myocardial infarction (within past 6 months)
- evidence of ischemia on functional cardiac exam within the last year) left ventricular ejection fraction <30%.
- Persistent elevation of liver function tests at the time of study entry.
- Symptomatic cholecystolithiasis.
- Acute or chronic pancreatitis.
- Symptomatic peptic ulcer disease.
- Gastrointestinal disorders potentially interfering with the ability to absorb oral medications.
- Hyperlipidemia despite medical therapy (fasting LDL cholesterol > 130 mg/dL, fasting triglycerides > 200 mg/dl).
- Chronic use of systemic steroids, except for the use of ≤5 mg prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only.
- Treatment with any anti-diabetic medications other than insulin within 4 weeks of enrollment.
23. Use of any investigational agents within 4 weeks of enrollment. 24. Administration of live attenuated vaccine(s) within 2 months of enrollment. 25. Any medical condition that, in the opinion of the investigator, will interfere with the safe participation in the trial.
26. Treatment with any immunosuppressive regimen at the time of enrollment. 27. A previous islet transplant. 28. A previous pancreas transplant 29. Inflammatory bowel disease. 30. History of intestinal obstructions. 31. Previous major abdominal surgery. 32. History of peritonitis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02213003
|United States, Florida|
|Diabetes Research Institute, University of Miami Miller School of Medicine|
|Miami, Florida, United States, 33136|
|Principal Investigator:||Rodolfo Alejandro||University of Miami|
|Responsible Party:||Rodolfo Alejandro, Professor of Medicine, University of Miami|
|Other Study ID Numbers:||
|First Posted:||August 11, 2014 Key Record Dates|
|Last Update Posted:||February 28, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Plan Description:||undecided. This is a small phase 1/2 pilot trial.|
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Endocrine System Diseases
Immune System Diseases